Increased Risk of Atrial Fibrillation in Migraine with Aura
These findings are among the first in the United States to indicate an association between migraine and atrial fibrillation.
BAN2401, a Promising Novel Treatment Against Alzheimer Disease
The positive topline results from Study 201 have led to the initiation of an open-label extension for the subjects previously enrolled in Study 201, which is set to begin later this year.
Chad Swanson, PhD, on the Promising Effect of BAN2401 on Alzheimer Disease Progression
The BAN2401 International Project Team Leader and Clinical Lead spoke about how the introduction of a novel, potentially disease modifying therapy would represent a paradigm shift in the field.
Galcanezumab Receives Breakthrough Therapy Designation for Prevention of Episodic Cluster Headache
Eli Lilly intends to submit a supplemental biologics license application to the FDA for galcanezumab for the preventive treatment of episodic cluster headache by the end of 2018.
Eli Lilly Submits NDA for Lasmiditan for Acute Treatment of Migraine
If approved, lasmiditan could represent the first significant innovation for acute treatment of migraine in more than 2 decades.
Ethical Issues Raised by Novel Therapies
The Carolyn and Matthew Bucksbaum Professor of Clinical Ethics at the University of Chicago spoke about the ethical considerations of spinal muscular atrophy and its treatment.
Lemborexant, Potential Therapy for Insomnia
The Founder and CEO of NeuroTrials Research spoke about the current landscape of insomnia, noting that lemborexant holds promise as a potential therapy.
Mandibular Movement Monitoring Can Assess Efficacy of Oral Sleep Apnea Devices
Tracking mandibular movements is a useful tool when measuring the efficacy of oral appliance therapy in obstructive sleep apnea.
Atrial Fibrillation Linked to Increased Risk of Dementia
Researchers found a link between atrial fibrillation and an increased risk of dementia and concluded that anticoagulants could help decrease that risk.
Epilepsy, the Perfect Paradigm in Implementing Telemedicine
The clinical professor in pediatric neurology and director of regional neurology services at Children's Hospital Colorado shared her thoughts on why epilepsy is the perfect paradigm to implement telemedicine.
Concomitant Use of Cholinesterase Inhibitors, Memantine May be Confounded with Outcomes in Alzheimer Clinical Trials
In clinical trials, differences in the use of cholinesterase inhibitors and memantine between treatment and placebo groups may lead to the conclusion that a treatment is effective when it is not, or vice versa.
Dystonia, A Disorder Longing for More Therapies
The Pediatric Movement Disorders Neurologist at UT Southwestern recommends that when encountering a patient with a movement disorder to organize your thought process in 3 steps.
AMBAR Data Revealed Significant Reduction in the Progress of Alzheimer Disease
Trial results showed a reduction of 61% in disease progression in both primary efficacy endpoints measuring cognition and activities of daily living at 14 months.
Spinal Muscular Atrophy, Questions That Remain Unanswered
Darryl De Vivo, MD, emphasized that while there's been a tremendous advance in the field of SMA, it’s important to continue tinkering around the margins to make the effective treatment increasingly better.
FDA Approves Expanded Use for Sodium Oxybate in Cataplexy, Excessive Daytime Sleepiness in Pediatric Narcolepsy
Sodium oxybate is the first therapy approved to treat cataplexy or excessive daytime sleepiness in pediatrics with narcolepsy 7 years of age and older.
Spinal Muscular Atrophy, From Bench to Bedside
The Sidney Carter Professor of Neurology at Columbia University Medical Center spoke about the 127 year history of spinal muscular atrophy and how basic science has led to exciting developments.
Generic Clobazam Tablets, Oral Suspension Receives FDA Approval for Lennox-Gastaut Syndrome
The approval and immediate launch of the product in both tablet and oral suspension offer a generic alternative to Onfi.
Richard Bogan on Excessive Daytime Sleepiness
The Associate Clinical Professor at the University of South Carolina School of Medicine and Chief Medical Officer at SleepMed emphasized that clinicians need to recognize the impact of sleepiness in terms of quality of life.
Alzheimer Disease Symptoms: More Than Memory Loss and Confusion
Neuropsychiatric symptoms are now recognized as hallmarks of dementia and are important targets for the development of effective treatments.
Lemborexant Met Primary, Secondary Endpoints in Phase 3 Insomnia Study
Both doses of lemborexant reduced subjective sleep onset latency for patients with insomnia.
New AUC for Lumbar Puncture, CSF Testing in Diagnosis of Alzheimer Disease
The guidance provides clinicians with tools allowing for earlier and more accurate diagnosis of Alzheimer disease.
Siponimod NDA Accepted by FDA for Secondary Progressive MS
If approved, siponimod would be the first oral disease-modifying therapy with the potential to delay secondary progressive multiple sclerosis progression.
Telehealth, Remaining Innovative as Technology Changes
The medical director of digital health at Cleveland Clinic spoke about the role telehealth plays in a society where technology constantly advances and changes.
Eric Pina-Garza, MD, on Perampanel For Pediatrics with Partial-Onset Seizures
The pediatric neurologist discussed the importance of the recent FDA approval of perampanel in pediatrics with partial-onset seizures with or without secondarily generalized seizures.
Restless Leg Syndrome Warrants More Attention, Expert Says
The restless leg syndrome expert spoke about the commonality of both pediatric and adult patients oftentimes misdiagnosed or undiagnosed with RLS.
The Importance of Telehealth with Peter Rasmussen, MD
Digital medicine is used to increase access for rural and underserved areas, allowing for the delivery of patient care, patient monitoring and specialist consultations.
Perampanel Receives Expanded Indication From FDA For Pediatrics With Partial-Onset Seizures
Safety data for pediatrics was consistent with the safety profile in adult populations, without the need for weight-based dosing.
In Alzheimer, Precision of Phrasing is Paramount
The Director of Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the importance of clarity in patient identification and assessment.
Alzheimer Disease, A Rapidly Changing Field
The Director of Cleveland Clinic Lou Ruvo Center for Brain Health spoke about the rapidly changing landscape of treatments for Alzheimer disease.
Restless Leg Syndrome, a Clinical Diagnosis
The Johns Hopkins Associate Professor spoke about the current therapeutic landscape of restless leg syndrome, an often misdiagnosed disorder.